-
-
-
-
-
-
News
-
-
Contact UsThe company focuses on the research, development, production, and sales of chemical raw materials and their formulations. All products have passed national GMP certification, and core products have successively passed official pharmaceutical regulatory certifications from multiple countries, including the EU EDQM, US FDA, Japanese PMDA, and South Korean MFDS. Following its successful listing on the Shenzhen Stock Exchange's ChiNext board on April 4, 2023, Keyuan Pharmaceutical has entered a phase of rapid development driven by both digital intelligence and capital, with its business spanning dozens of countries and regions worldwide.
Historical Evolution
December 2025
The world’s first single‑nitrate continuous‑flow plant has successfully completed its trial run.
September 2025
The AI‑powered, compute‑intensive smart factory for Lino Pharmaceutical’s injectable products has been completed.
May 2025
Koyuan Pharmaceutical (Guangzhou) Co., Ltd. was officially established.
February 2025
Koyuan Pharmaceutical (Shanghai) Co., Ltd. was officially established.
June 2024
Metformin hydrochloride, palonosetron hydrochloride, and rotigotine APIs have been re-certified by the FDA; methylene blue API has been certified by the FDA.
November 2023
Signed an equity cooperation agreement with Beijing Nuokangda Pharmaceutical, which became the Beijing R&D center.
April 2023
Successfully listed on the Shenzhen Stock Exchange's ChiNext board, stock code 301281.SZ
Address: No. 26, Keyuan Street, Shanghe County, Jinan City, Shandong Province
Free Service Hotline